Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NUVL 
Nuvalent Inc (NUVL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NUVL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $117.33
1 Year Target Price $117.33
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.86% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.65B USD | Price to earnings Ratio - | 1Y Target Price 117.33 |
Price to earnings Ratio - | 1Y Target Price 117.33 | ||
Volume (30-day avg) 11 | Beta 1.29 | 52 Weeks Range 55.53 - 108.98 | Updated Date 09/16/2025 |
52 Weeks Range 55.53 - 108.98 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.37% | Return on Equity (TTM) -43.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4717362911 | Price to Sales(TTM) - |
Enterprise Value 4717362911 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.26 | Shares Outstanding 66669600 | Shares Floating 41557623 |
Shares Outstanding 66669600 | Shares Floating 41557623 | ||
Percent Insiders 2.84 | Percent Institutions 109.13 |
Upturn AI SWOT
Nuvalent Inc
Company Overview
History and Background
Nuvalent, Inc. is a biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. Founded in 2017, it went public via a SPAC merger in 2021. The company's focus is on developing kinase inhibitors to overcome resistance and improve outcomes for cancer patients.
Core Business Areas
- Precision Oncology: Developing small molecule kinase inhibitors targeting specific oncogenic drivers in cancer.
Leadership and Structure
The company is led by James Porter, PhD, as CEO. The organizational structure includes research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- NVL-520: A ROS1-selective inhibitor designed to address resistance mutations in ROS1-positive non-small cell lung cancer (NSCLC) and other cancers. Market share data is still developing as it is in clinical trials. Competitors include Roche's Rozlytrek and Pfizer's Xalkori.
- NVL-655: An ALK-selective inhibitor designed to address resistance mutations in ALK-positive NSCLC and other cancers. Market share data is still developing as it is in clinical trials. Competitors include Takeda's Alunbrig and Novartis' Zykadia.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by an aging population and advancements in cancer diagnostics and treatment. Precision oncology is a key trend, with increasing focus on targeted therapies.
Positioning
Nuvalent is positioned as a precision oncology company developing selective kinase inhibitors to address resistance mechanisms in cancer. Its competitive advantage lies in its focus on highly selective inhibitors and addressing unmet needs in specific patient populations.
Total Addressable Market (TAM)
The total addressable market for targeted cancer therapies is estimated to be in the billions of dollars. Nuvalent is positioned to capture a portion of this market by developing therapies for specific subsets of cancer patients with resistance mutations.
Upturn SWOT Analysis
Strengths
- Strong focus on precision oncology
- Pipeline of highly selective kinase inhibitors
- Experienced management team
- Strong intellectual property position
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Competition from established pharmaceutical companies
Opportunities
- Potential to develop first-in-class therapies
- Expanding market for targeted cancer therapies
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other targeted therapies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ROSE
- PFE
- TAK
- NVS
Competitive Landscape
Nuvalent is focused on overcoming resistance to existing kinase inhibitors. Its competitive advantage lies in developing highly selective inhibitors with improved safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Nuvalent's historical growth is measured by the advancement of its clinical pipeline and increase in its market capitalization.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential regulatory approvals. Analyst estimates vary but generally project significant revenue growth in the coming years if its lead candidates are approved.
Recent Initiatives: Recent initiatives include advancing NVL-520 and NVL-655 through clinical trials and expanding its pipeline with new research programs.
Summary
Nuvalent is a clinical-stage biopharmaceutical company with a strong focus on precision oncology and developing highly selective kinase inhibitors. The company is working on addressing significant unmet needs in cancer treatment. It faces the typical risks of clinical development and competition. Success hinges on positive clinical trial outcomes and securing regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvalent Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-29 | CEO, President & Director Dr. James R. Porter Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 200 | Website https://www.nuvalent.com |
Full time employees 200 | Website https://www.nuvalent.com | ||
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.